Introduction
Brain tumors are one of the most lethal forms of human cancer. The most common malignant brain tumors of adulthood and childhood respectively are gliomas and medulloblastomas. A particularly aggressive form of brain tumor is glioblastoma multiformed (GBM), which is characterized by chemo-and radiation resistance with median survival approximately 12 months. 2 Medulloblastoma is a malignant tumor typically occurring in the cerebellum of children and young adults. Clinical management of medulloblastoma is more successful than gliomas with 5 year event-free survival of around 70%. One of the reasons why brain tumors remain so difficult to treat has been the limited understanding of the underlying biology, and a lack of accurate models that histologically and genetically mimic human gliomas and medulloblastomas. Another reason for poor responsiveness is tumor heterogeneity, as there is increasing evidence from different laboratories that brain tumors arise from diverse set of molecular abnormalities. However, all patients with a diagnosis of a particular brain tumor and stage are treated identically, without regard to the underlying genetic differences. Most preclinical studies are performed in cell lines or xenografts that have been cultured as a monolayer on plastic for decades, but studies have shown that tumor cells cultured in such conditions exhibit substantially different gene expression profiles, genotype and biology compared to their parental primary tumors within a short time. 3 Within the last several years, evidence from different laboratories have shown that cancers are most effectively serially passaged by rare fractions of cancer stem cells (CSCs) , that exhibit self-renewing, multipotent, and tumorinitiating capacity. [4] [5] [6] [7] Despite intensive studies in the field regarding the origin of brain tumors, the response to therapy of cancer stem cells and tumor bulk in their native microenvironment, has not been studied. In this review we will concentrate on Sonic Hedgehog (SHH) pathway driven medulloblastomas, and discuss our recent study on their therapeutic response to radiation in the context of genetic mouse models of this disease. 1 
Neural Stem Cells
Researchers in the field of radiation biology were the first to formulate the concept of stem cells. The term stem cell was coined in the context of clonogenic cells that have retained the capacity for producing a large number of progeny after treatments that can cause cell reproductive death as a result of damage to chromosomes, apoptosis, etc. 8 In 1961 stem cells (hematopoetic stem cells) from the bone marrow of mice were shown to produce colonies reproducibly in spleens of heavily irradiated recipient animals. 9 Later it was shown that skin stem cells were able to produce nodules in the irradiated skin of mice after doses that impair proliferation of the majority of cells in a selected small area. In addition, stem cells in the crypts of mouse jejunum were shown to produce colonies in heavily irradiated regions of the intestine. 10 In the normal adult brain there are several areas that are thought to harbor stem cells. Nestin and GFAP double positive astrocytes in the subventricular zone (SVZ) are thought to be the stem cells, which divide to generate transit-amplifying cell, which in turn generate the neuroblasts that migrate to the olfactory bulb. 11 In addition, several other groups have shown neurogenesis in the subgranular zone (SGZ) of dentate gyrus in the hippocampus. [12] [13] [14] [15] The murine postnatal cerebellum was also reported to contain multipotent stem cells located in the white matter that can be isolated based on expression of CD133. 16 Other neurogenic regions are thought to exist in the adult brain and further studies to identify them are in process. Thus it appears that the brain harbors multipotent stem cells which reside in specialized locations that support self-renewal, and differentiation. 17 Stem cells in association with other cells create a special microenvironment, which in turn determines their behavior. Those structures have been termed the stem cell "niche" 18 Adult stem cell niches differ in their cellular composition, structure and location in different tissues. The stem cell niche is a complex structure that contains different cell types and is critical for maintaining stem cell properties. For example, it was shown that in adult bone marrow, hematopoetic stem cells are located in the trabecular endosteum (osteoblastic niche) or sinusoidal perivascular (vascular niche) areas. 19, 20 Studies on the mouse brain suggest that neurogenesis occurs within a vascular niche where endothelial cells regulate stem cell renewal. [21] [22] [23] There are several reports showing that developmental pathways such as Notch, SHH and Wnt, are active in stem cell niches. For example, activated Notch signaling appears particularly capable of affecting both tumorigenesis and stem cell development, and it is necessary for maintaining a pool of undifferentiated stem cells. 24, 25 Deletion of Notch1 results in a decrease in neural stem cells and reduction in their proliferation. 26 Later studies have expanded the known functions of Notch to include important cell fate decisions throughout glial and neuronal development. In the oligodendrocyte lineage, Notch activation has been shown to suppress terminal oligodendrocyte differentiation but also support the specification of oligodendrocyte precursors from the initial stem cell pool. 27, 28 Notch signaling can promote the specification of Muller glia in the rat retina, 29, 30 radial glia in the telencephalon from cortical stem cells, 31 and astrocytes in the adult brain from hippocampal multipotent progenitors. 32 A simplified schematic of the Notch signaling pathway is illustrated in Figure 1A .
SHH signaling regulates multiple aspects of CNS development, controlling both cell proliferation and cell differentiation. SHH is required for the differentiation of floor plate cells and ventral neurons in the early neural tube. 33, 34 SHH also regulates proliferation of granule cell precursors in the developing cerebellum 35 and contributes to oligodendrocyte specification in the mammalian forebrain. 36, 37 Furthermore, SHH is necessary and sufficient for oligodendrocyte precursor production in cortical neuroepithelial cultures, 38 and drives proliferation in CNS precursor cells. 39 Lastly the SHH pathway is active in both the SVZ and SGZ of adult mice, where astrocytes are thought to release SHH that stimulate neuronal progenitors to re-enter the cell cycle and generate new neurons in vivo and in vitro. 40 A schematic of the SHH signaling pathway is illustrated in the (Fig. 1B) .
The role of Wnt canonical signaling in the CNS stem cell niches is also well defined. It has been shown that Wnt signaling transiently stimulates proliferation and enhances neurogenesis in neonatal neural progenitor cultures. 41 It was suggested that beta-catenin signaling plays a role in the proliferation of progenitor cells in the SVZ of the adult mouse, 42 and regulate stem cell fate and differentiation in vivo. 43 Wnt3a was shown promotes neuronal differentiation of neuronal stem cells derived from adult mouse spinal cord. 44 The Wnt signaling pathway is illustrated in (Fig. 1C) .
Cancer Stem Cells and the Niche
The concept of cancer stem cells (CSCs) has been used over 50 years, but evidence supporting their existence has strengthened significantly in the last few years. In 1989, Hill and Milas suggested that murine tumors contain stem cells and that the number of these cells within the tumor can be important determinants of prognosis. 45 In the last several years, evidence has grown in support of the theory that cancers have their own stem cells, supporting the notion that the neoplastic process maintains the hierarchical structure of the normal tissue from which it is derived. CSCs have been identified in leukemias, breast, pancreatic, prostate, head and neck and colon cancer. 6, [46] [47] [48] [49] [50] Since then active discussion regarding cancer stem cell theory of tumor formation was initiated. [51] [52] [53] [54] The presence of CSCs was also shown in brain tumors. 5 More recently several studies have identified CD133 (prominin-1) as a stem cell surface marker for gliomas and demonstrated that the number of these cells varies greatly, ranging from 1% in low grade brain tumors to 25% in high grade gliomas. 7, 55, 56 Cancer stem cells in the brain (CSCs) express not only CD133 but also nestin, which is activated by Notch signaling. 57, 58 Nestin is known to be a marker for poor prognosis in gliomas, and a neuronal stem/progenitor marker in both the adult and developing brain. 59 CD133 + subpopulations isolated from glioma, medulloblastoma and ependymoma were able to initiate and sustain tumor growth in xenograft experiments. 7, 56, 60 Besides CD133, the side population (SP) phenotype, defined by its ability to efflux the nucleic acid-staining dye Hoechst 33342, has been used to prospectively isolate a small percentage of cells in brain tumors uniquely able to generate tumor neurospheres and xenografts. 61 Finally, Calabrese et al. showed that brain tumor stem cells exist in a perivascular niche, providing evidence that the microvasculature forms scaffolding that may be necessary for maintaining or promoting the cancer stem cell phenotype. 57, 62 Later it was demonstrated that the SHH signaling pathway is active in gliomas and it correlates with tumor grade. SHH expressing reactive astrocytes were shown to reside in the perivascular stem cell niche in a mouse model of PDGF-driven gliomas next to nestin expressing stem cells suggesting similarities between normal and cancer stem cells. 40, 63 Finally CD133 + cells have been termed tumor-initiating cells (CD133 -cells did not form tumors when implanted in immunocompromised mice) based on data obtained in the above-mentioned publications. The uniformity of CD133 as a marker for brain tumor stem cells has been questioned however. A recent study demonstrated that a series of secondary glioblastomas do not have any CD133-expressing cells, while 70% of primary glioblastomas have cells that are CD133 positive with CSC-like properties. 64 More recently, a separate group demonstrated that CD133 -tumor cells are capable of self-renewal and can give rise to tumors with CD133 + cells. 65 These data together suggest that CD133 is expressed on cells with stem cell properties in a subset of gliomas. Finally, two recent studies identified molecular differences between histologically identical glial cell tumors arising in distinct CNS locations, with molecular similarity to the normal cells in the location of the tumor suggesting heterogeneity in cells that can fit the definition of cancer stem cells. 56, 66, 67 Cancer Stem Cells and Resistance to Therapy Several studies were initiated to study the effect of radiation therapy and different small molecule inhibitors on CSCs from different tumor types. After CD133 was identified as a marker for brain tumor stem cells, several reports studying response of CSCs to different anti-cancer strategies followed. Bao et al., demonstrated that CD133 + cells contribute to glioma radio-resistance via preferential activation of DNA damage checkpoints, and that their resistance could be partially reversed with specific inhibitors of Chk1 and Chk2. 68, 69 Two other groups have shown that the bone morphogenetic proteins (BMPs) and cannabinoids inhibit the tumorogenic potential of CD133 + cancer stem cells and promote their differentiation. These results are intriguing because they present an opportunity to develop a new approach for GBM treatment based on the induction of differentiation of CD133 + cells, rather than killing them. 70, 71 DAOY medulloblastoma cells expressing CD133 showed more radioresistance as compared to the CD133 -negative population, and in hypoxic conditions the number of CD133 expressing cells were increased. 72 Besides their relative radioresistance, CSCs express high levels of multiple drug-resistance genes than the differentiated tumor bulk 73 and show significant resistance to the chemotherapeutic agents. 74 SHH pathway inhibitors can inhibit the growth of medulloblastoma but not other brain tumors in mice, 75, 76 and inhibition of the Notch pathway by using γ-secretase inhibitors blocks CSC self-renewal and decreases mouse medulloblastoma growth. 77 Most of these studies were performed in isolated cancer cells in in vitro conditions in the absence of the perivascular niche. The niche is known to provide an umbrella that protects stem cells from differentiation stimuli, apoptosis and other stresses that affect stem cells. 78 Therefore, it is important to study the response of stem cells to therapy in their intact niche. As gliomas are more complex as well as more resistant to radiation treatment (unpublished observations), we investigated the radiation resistance of CSCs in a brain tumor model that is known to be radiation sensitive: medulloblastoma.
Medulloblastoma Mouse Models
Medulloblastoma is an embryonal round blue cell tumor that arises in the cerebellum, mostly in children. There are about 350 new diagnoses of medulloblastoma in the United States per year. Over the last twenty years there has been an increasing awareness of the genetic alterations that drive medulloblastoma pathogenesis. This has been achieved mainly through genetically engineered mouse models. We now know that about of a third of medulloblastomas are due to abnormal activation of the hedgehog pathway. About 25% are due to alterations of the wingless pathway (Wnt), which is interestingly associated with a better prognosis. 79 One additional genetic alteration that is common but of unknown significance is isochromosome 17. 80 Additional less common genetic alterations include c-myc amplification, and mutations in p53. There are several common histologies of human medulloblastomas: desmoplastic, classic, extensive nodularity histology and large cell anaplastic histologies. The desmoplastic histology correlates with activation of the hedgehog pathway, 81 while the large cell anaplastic (LCA) histology correlates with c-myc amplification and/or p53 mutations. 82, 83 One additional genetic alteration that has been associated with prognosis is ERB-B2 overexpression but it has not been shown to correlate with a particular histology. 84 From a clinical standpoint, the management of medulloblastoma is mainly based on the stage at which it is diagnosed or the extent of disease. Newly diagnosed patients with medulloblastoma undergo a brain and spine MRI, a lumbar puncture and sometimes additional tests as clinically indicated. Patients are classified as standard risk if all three of the following conditions are met: complete surgical resection leaving less than 0.5 cm 2 of residual tumor, patients are between the ages of 3-10 years of age, and patients do not have other foci of disease. High-risk patients are those that do not meet all of the criteria for standard risk disease. Standard risk patients receive 2340 cGy of craniospinal radiation fractionated into daily dose of 180 cGy. In addition, they receive a boost to the primary tumor bed up to 55.8 cGy. Patients also receive chemotherapy after completion of radiation with most commonly eight cycles of vincristine, lomustine and cisplatin. Of these three chemotherapeutic agents, cisplatin is thought to be the most active agent. In general the prognosis for patients with standard risk medulloblastoma is good, currently with 5-year eventfree survival (EFS) of around 85%. In contrast, the prognosis for high-risk patients is around 60-70% 5-year EFS and they require more intensive therapy. Patient with recurrent medulloblastoma following treatment have a significantly worse prognosis. 85 There are numerous mouse models of medulloblastoma most of which involve activation of the sonic hedgehog pathway. 80 The first reported model for this tumor was the Ptc +/-model in mice where lacZ is knocked-into the Ptc locus. 86 These mice develop medulloblastomas at a rate of 10%-15% by 12 months of age. When crossed with p53 null mice, these mice generate medulloblastomas at a high rate of 95% by 3 months. 87 Another transgenic mouse where an activated smoothened allele is expressed under the control of the NeuroD2 promoter develop medulloblastomas at a rate of 48% by approximately 6 months. 88 Another SHH driven medulloblastoma model uses the RCAS/tv-a system where overexpression of SHH in nestin-expressing progenitor cells of the cerebellum (there are nestin expressing cells in the external granule layer at P1-P2) results in 15% incidence of medulloblastomas by 3 months. 89 The incidence of medulloblastomas using this model can be increased by co-infecting nestin progenitor cells with RCAS vectors expressing Akt, N-myc, IGF2 or BCL-2. [90] [91] [92] Lastly, the minor subtype of medulloblastoma, namely medulloblastoma with extensive nodularity can be generated using the RCAS/tv-a system by overexpressing SHH with loss of PTEN in nestin-expressing progenitor cells from the external granular layer (EGL). 1 There is also an in utero medulloblastoma model where SHH is injected via a retrovirus into 13.5-day embryos. 93 In addition, there have been numerous models of medulloblastoma which are generated by crossing p53 null mice with mice lacking DNA repair pathway proteins or key cell cycle regulators such as Lig4, Ink4c, PARP, BRCA2 and XRCC4. [94] [95] [96] [97] [98] Another medulloblastoma model involves overexpression of interferon gamma in astrocytes 99 and CXCR6 -/-mice also develop medulloblastomas. 100 There is only one medulloblastoma model that demonstrates Wnt pathway activation-a transgenic mouse that overexpresses the human neurotropic virus (JCV virus). 101, 102 In addition there are now mouse models of medulloblastomas of the LCA subtype. The first one was generated by crossing double conditional p53 and Rb mice with GFAP-Cre mice. 103 The second one uses the RCAS/tv-a system whereby overexpression of c-Myc and β-catenin in GFAP expressing cerebellar progenitors in GFAP-tva mice in a p53 null background results in a large cell anaplastic (LCA) histology. 104 Both of these models target the same cell of origin (GFAP-expressing cells) with loss of p53. This is consistant with human LCA meduilloblastomas having alterations in p53. 82 Table 1 presents a summary of existing genetically engineered mouse models for medulloblastoma.
To ensure that our observations were not specific to a single model of medulloblastoma, we used two mouse models to study the response of medulloblastoma to radiation: Ptc +/-mice and the RCAS/ tv-a system. When we irradiated medulloblastoma-bearing mice with a single dose of 2 Gy, we noted a dramatic apoptotic response by 6 hours. This response can be visualized using a Gli-luc reporter mouse, which provides a bioluminescent imaging readout of the hedgehog pathway in vivo to measure the therapeutic response. In Fig. 2A and B, we imaged a medulloblastoma-bearing mouse before and six hours post-2 Gy single-dose radiation. While the Gli-luc output was dramatically reduced, histologic analysis demonstrated that there are surviving perivascular cells. Further analysis of the surviving cells demonstrated that they express nestin (a subset also expresses GFAP as well as Olig-2) and undergo cell cycle arrest in response to radiation. Furthermore, these cells re-enter the cell cycle at 72 hours and give rise to tumor recurrence. Although the complete mechanism by which nestin-expressing stem cells resist radiation is not known, these cells activate the Akt pathway in response to radiation. The upstream and downstream consequences of this event are unclear but not surprisingly the nestin-expressing stem cells activate p53 in response to radiation at 6 hours, and tumor bulk at 4 hours.
PI3K/Akt Pathway in Medulloblastoma
Akt is activated by many mechanisms including loss of PTEN. In the extensive nodularity medulloblastoma model, PTEN loss in the stem cell niche activates Akt, mTOR and S6K in the-nestin expressing stem cells and thus mediates radiation resistance. In the tumor bulk, loss of PTEN results in the differentiation of the tumor cells to express NeuN 82 ( Fig. 3A and B) . Akt/PKB is 57 KDa Ser/Thr kinase downstream of phosphatidylinositol 3'-kinases (PI3K). It represents a key mediator of the signal transduction of different growth-controlling pathways. Upon stimulation by different growth factor and ionizing radiation PI3K catalyzes the generation of phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol-4,5-triphosphate (PIP2). PIP3 levels are regulated by lipid and protein phosphatase PTEN/MMAC. PIP3 recruits Akt into the plasma membrane where it is activated via phosphorylation. Several downstream targets of Akt have been identified (e.g., the BCL-2 family member BAD, caspase-9, MDM2, the transcription factor Forkhead, and glycogen synthase kinase 3-β (GSK-3β), thus conferring to Akt an important role in the regulation of growth and cell survival signaling pathways. [105] [106] [107] [108] [109] In studies of RCAS/t-va mouse model by Fults et al. it was demonstrated that PI3K/Akt signaling pathway contributes to SHH induced medulloblastoma formation. 92 Activation of PI3K/Akt pathway is an important step in the molecular pathogenesis of human medulloblastoma and it is associated with reduced expression of PTEN 110 through deletion or methylation. 111 The first study demonstrating the role of the Akt pathway specifically in cancer stem cell resistance to chemotherapy was a study showing, that CD133 positive CSCs from hepatocellular carcinoma (HCC) contribute to chemoresistance through preferential activation of the Akt/PKB and BCL-2 cell survival pathways. 112 Using SHH driven murine medulloblastoma models, we demonstrate that the Akt pathway is responsible for radiation resistance of CSCs in their native microenviroment. By using the Akt inhibitor perifosine we were able to sensitize a subset of CSCs to radiation induced apoptosis. Our data together with others demonstrate the role of the Akt pathway not only in tumor initiation but also in determining CSC resistance to radiation. 1, 92 As the Akt pathway seems to be a general survival pathway in cancers, inhibition of this pathway to address the biology of specific cell types may have benefit for the treatment of patients with cancer in general. 
